7 results about "Salmonella dan" patented technology

The present invention relates to immunogenic compositions comprising antigens derived from Salmonella enterica serotype tiphimurium (S. Typhimurium), Salmonella enterica serotype enteritidis (S. Enteritidis), and Salmonella enterica serotype typhi (S. Typhi). The present invention further relates to methods and compositions comprising GMMA for boosting the immune response to the S. Typhi antigen, vaccines and methods comprising immunogenic compositions, and the use of immunogenic compositions.

A yeast biomass composition is formed by culturing a strain of yeast in a substrate such as whey permeate to product a yeast broth, dewatering the broth to produce yeast biomass, and hydrolysing the yeast biomass. The yeast biomass composition finds utility as a feed additive for broiler chickens to reduce the adherence of pathogenic bacteria like Salmonella and E.coli to the gut wall of the chickens, thereby reducing intestinal stress and improving life daily weight gain in the chickens.

The invention relates to small molecule compounds that are useful as antimicrobial agents, pharmaceutical compositions comprising the compounds, and the use of the compounds in the treatment of subjects with microbial infections.

The application discloses a Salmonella phage nct1, and the Salmonella phage nct1 (Salmonella phage nct1) has a preservation number of CCTCC NO: M 20221037. The Salmonella phage nct1 has small toxic and side effects, high safety, a relatively wide temperature and acid-base tolerance range, and good killing and prevention and control effects on environments, foods and the like contaminated by Salmonella and pathogenic Escherichia coli.

The application discloses a kind of attenuated salmonella and amodiaquine combined medicine and application, attenuated salmonella and amodiaquine combined medicine include attenuated salmonella typhimurium VNP20009 and its derivative or genetically modified strain and amodiaquine as active component.Amodiaquine is selectively eliminated neutrophil in tumor microenvironment by targeting binding glutathione reductase in neutrophil and inhibiting its activity.Amodiaquine of the application directly targets glutathione reductase in neutrophil, inhibits its activity, reduces reduced glutathione level, increases active oxygen accumulation, selectively induces neutrophil apoptosis in tumor immune microenvironment, and further enhances the colonization of VNP20009 and its derivative or genetically modified strain in tumor.The combination therapy reduces tumor weight by about 50%, prolongs tumor growth doubling time by 1.5 times, and does not affect the neutrophil level in peripheral blood and important organs, significantly reduces the liver and kidney toxicity of VNP20009 and its derivative or genetically modified strain.

The present application relates to the technical field of Salmonella bacteriophage, and particularly relates to a bacteriophage capable of lysing Salmonella Blegdam (Salmonella Blegdam bacteriophage) and a composition and application thereof. The bacteriophage is Salmonella bacteriophage RDP-SA-22010, the preservation number of which is CGMCC No. 45274, and the bacteriophage was preserved in the China General Microbiological Culture Collection Center on September 21, 2022. The Salmonella bacteriophage RDP-SA-22010 can also lyse Salmonella enteritidis, Salmonella pullorum and Salmonella kentucky. A composition comprises the Salmonella bacteriophage RDP-SA-22010. A reagent or kit comprises the above-mentioned composition. The present application also provides that the Salmonella bacteriophage RDP-SA-22010 can be applied to the preparation of a biological sterilizing agent, the preparation of a medicine for treating diseases caused by Salmonella and the preparation of a feed additive. The Salmonella bacteriophage RDP-SA-22010 in the present application provides a new biological control means for the prevention and treatment of Salmonella Blegdam.

This invention discloses an amplification-free time-resolved fluorescence lateral chromatography method for detecting Salmonella and drug-resistant strains, belonging to the field of rapid detection technology. Based on CRISPR / Casl2a technology, this invention designs crRNAs targeting Salmonella and drug-resistant Salmonella strains. The crRNAs shown in SEQ ID NO. 1–SEQ ID NO. 8 can specifically detect Salmonella and drug-resistant Salmonella strains, while the crRNAs shown in SEQ ID NO. 9–SEQ ID NO. 14 can specifically detect drug-resistant Salmonella strains, effectively distinguishing between Salmonella and drug-resistant Salmonella strains. The time-resolved fluorescence kit for drug-resistant Salmonella provided by this invention achieves a detection limit (LOD) of 1.8 × 10⁻⁶. 2 With a concentration of CFU / mL, and high precision and accuracy, this technology enables effective and rapid screening and detection.